Zepbound side effects: every rate on the FDA label
The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease. (6.1) dailymed.nlm.nih.gov, Sep 27, 2026
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS
dailymed.nlm.nih.gov, Sep 27, 2026In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.
dailymed.nlm.nih.gov, Sep 27, 2026
How often each side effect happened
| Side effect | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal Pain | 5% | 9% | 9% | 10% |
| Dyspepsia | 4% | 9% | 9% | 10% |
| Injection Site Reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Eructation | 1% | 4% | 5% | 5% |
| Hair Loss | 1% | 5% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
Percent of people in the trial who reported it. Placebo is the comparison group.
Who stopped because of side effects
- Discontinued for adverse reactions: 4.8% / 6.3% / 6.7% (5/10/15 mg) vs 3.4% placebo.
Across both trials, 4.8%, 6.3%, and 6.7% of patients treated with 5 mg, 10 mg, and 15 mg of ZEPBOUND, respectively, permanently discontinued treatment as a result of adverse reactions compared to 3.4% of patients treated with placebo. The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions.
dailymed.nlm.nih.gov, Sep 27, 2026
Who should not take it, pregnancy and breastfeeding
- Contraindicated with personal/family history of MTC or MEN 2.
A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Contraindicated with known serious hypersensitivity to tirzepatide or excipients.
Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions (5.6) and Adverse Reactions (6.2)].
dailymed.nlm.nih.gov, Sep 27, 2026 - Pregnancy: weight loss offers no benefit; stop Zepbound when pregnancy is recognized.
Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized
dailymed.nlm.nih.gov, Sep 27, 2026 Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue ZEPBOUND. (8.1)
dailymed.nlm.nih.gov, Sep 27, 2026- Lactation: tirzepatide in breast milk undetectable or low in a single-dose study.
In a single-dose clinical lactation study, the concentration of tirzepatide in breast milk was found to be either undetectable or low compared to the maternal administered dose (see Data).
dailymed.nlm.nih.gov, Sep 27, 2026
Label revised 8/2026: read the full label on DailyMed. The label lists more reactions and warnings than this page.
Doses and schedule: Zepbound dosing · Price: Zepbound cost · All medications: side effects compared
This page reports what the label says; it is not medical advice. Tell your prescriber about any side effect.Medical disclaimer.